Showing 271-280 of 2128 results for "".
What Dermatologists Ought to Know About Cyspera®
https://practicaldermatology.com/topics/general-topics/what-dermatologists-ought-to-know-about-cyspera/20103/Cyspera has become a "go-to topical product for pigment," says Michael H. Gold, MD. He describes the Cyspera Intensive System and its benefits for the management of hyperpigmentation. He discusses advancements in the Cyspera formulation that enhance outcomes.Energy-based Devices for Fat Reduction
https://practicaldermatology.com/conferences/maui-derm-2024/energy-based-devices-for-fat-reduction/20236/Michael H. Gold, MD, founder and medical director of the Gold Skin Care Center in Nashville, highlights new energy-based devices for fat reduction, including those utilizing lasers and radio frequency technology for muscle stimulation.Laser Tattoo Removal and the Use of Stacked Treatments
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/laser-tattoo-removal-and-the-use-of-stacked-treatments/19309/Tattoo removal procedures have been offered since the late 1990's, but are more effective than ever. This improvement is due to the implementation of stack treatments, during which four sessions can be performed at one time. To show the advances in this procedure, Dr. Joel Schlessinger walks you thrScientifically Speaking: Expert Filler Tips and Cases
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-expert-filler-tips-and-cases/20005/Optimal outcomes with aesthetic injectables depend on choosing the right filler and applying the proper technique. Michael Somenek, MD; Kay Durairaj, MD; Shino Bay Aguilera, DO; and Corey Hartman, MD share cases and discuss the secrets to natural-looking, impressive improvements in the lips, chin,Intergenerational Dermatology: Two Generations of Dermatologists Reflect on the Field
https://practicaldermatology.com/topics/general-topics/intergenerational-dermatology-two-generations-of-dermatologists-reflect-on-the-field-2/23937/With Heidi A. Waldorf, MD, and Donald S. Waldorf, MDCrisis Management: Office Operations, Part 1
https://practicaldermatology.com/topics/practice-management/crisis-management-office-operations-part-1/18181/How are primarily cosmetic dermatology practices dealing with shutdowns and preparing for the future? Host Neal Bhatia, MD discusses with Deirdre Hooper, MD, Ashish Bhatia, MD, Kevin Pinski, MD, and Nancy Samolitis, MD.New and Emerging Treatments in Aesthetic Dermatology
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/new-and-emerging-treatments-in-aesthetic-dermatology/18819/Joel Cohen, MD provides an update on innovative treatments in aesthetic dermatology that have really blossomed in the last year, such as combination non-ablative and ablative fractional and bipolar radiofrequency. He also says there are now great modalities to treat the whole patient—from the neck,Systemic Implications of Psoriasis
https://practicaldermatology.com/topics/psoriasis/systemic-implications-of-psoriasis/18636/Although a disease with a presentation on the skin, psoriasis has important implications for systemic health. Joel Gelfand, MD, talks about the increased risk for diabetes and cardiovascular disease in patients with psoriasis, as well as the clinician's role in educating patients about their diseasePsoriasis Update 2025: Dr. Gelfand
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/psoriasis-update-2025-dr-gelfand/32672/Joel Gelfand, MD, MSCE, discusses highlights from the "Psoriasis Update 2025" panel at Maui Derm 2025, including the potential for combining TNF inhibitors with IL-23 inhibitors; home phototherapy; and the possibility of GLP-1 agonists lowering the severity of psoriatic disease.Toxin Time: What’s New and Exciting with Neuromodulators
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/toxin-time-whats-new-and-exciting-with-neuromodulators/19768/Joel Cohen, MD takes a deep dive into the most recent data on neuromodulators including post-hoc analyses on the potential durability of response. Dr. Cohen also shares updates on Revance’s DAXI, Botox Cosmetic and liquid toxins under development by Galderma and Allergan.